PR

Prestige BioPharma Limited

Develops affordable biosimilars and novel antibody drugs for life-threatening diseases.

950210 | KO

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Singapore
Address:
21 BIOPOLIS ROAD #04-24 NUCLEOS, SINGAPORE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Prestige BioPharma Limited is a biopharmaceutical company specializing in the development of biosimilars and innovative, first-in-class antibody drugs. The company pursues a dual-track strategy focused on both creating affordable, high-quality biosimilars to enhance patient access and discovering novel therapeutics and vaccines for life-threatening diseases. Its operations cover the full development lifecycle, from discovery and research to clinical development, registration, and commercialization. Prestige BioPharma aims to become a global innovation hub by fostering collaboration and advancing biopharmaceutical technologies.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Prestige BioPharma Limited and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-09-19 00:00
Audit Report / Information
감사보고서제출
Korean 21.8 KB
2025-09-19 00:00
Annual Report
사업보고서 (2025.06)
Korean 3.7 MB
2025-09-16 00:00
Regulatory News Service
[기재정정]단일판매ㆍ공급계약체결
Korean 12.8 KB
2025-09-11 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 17.3 KB
2025-09-11 00:00
Pre-Annual General Meeting Information
주주총회소집공고
Korean 136.7 KB
2025-09-09 00:00
Pre-Annual General Meeting Information
주주총회소집결의
Korean 9.5 KB
2025-08-18 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 8.6 KB
2025-08-13 00:00
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변경
Korean 19.1 KB
2025-07-31 00:00
Regulatory News Service
[기재정정]투자판단관련주요경영사항 (특허권 취득)
Korean 15.7 KB

Automate Your Workflow. Get a real-time feed of all Prestige BioPharma Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Prestige BioPharma Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SEYİTLER KİMYA SANAYİ A.Ş. Logo
Manufacturer of medical tapes, wound dressings, and first aid plasters for the healthcare industry.
Türkiye SEYKM
Shaperon Inc. Logo
Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.
South Korea 378800
Shedir Pharma Group Logo
Develops and sells pharmaceutical, nutraceutical, and dermo-cosmetic products in Italy & Spain.
Italy SHE
SHIELD THERAPEUTICS PLC Logo
Commercializing a novel oral therapy for adults with iron deficiency.
United Kingdom STX
SHINPOONG PHARMACEUTICAL CO.,LTD Logo
R&D-driven pharma firm making APIs, finished drugs, and medical products for global markets.
South Korea 019170
Shionogi & Co.,Ltd. Logo
A research-driven pharmaceutical firm creating drugs, diagnostics, and devices for global health.
Japan 4507
Siegfried Holding AG Logo
Global CDMO providing development and manufacturing of APIs and finished drugs for the pharma industry.
Switzerland SFZN
Develops oncolytic viruses and immunotherapeutics to destroy difficult-to-treat cancer cells.
South Korea 215600
SK biopharmaceuticals Co., Ltd. Logo
Develops and commercializes CNS and oncology therapies for global markets, focusing on the U.S.
South Korea 326030
SK Bioscience Co.,Ltd Logo
A global biotech firm developing vaccines for diseases like COVID-19, influenza, and shingles.
South Korea 302440

Talk to a Data Expert

Have a question? We'll get back to you promptly.